GlucoTrack (Nasdaq:GCTK) announced today that it appointed Mark Tapsak as its vice president of sensor technology.
Tapsak, a veteran of more than 25 years in the diabetes industry, joins the company, effective immediately. His experience includes time spent as a medical device research scientist. He focused on polymer synthesis, polymer characterization, medical device design and intellectual property.
In his new role at GlucoTrack, Tapsak’s responsibilities include leading a new R&D program. The company announced earlier this week that it plans to expand its product pipeline with an R&D program. The program centers around developing a long-term continuous glucose monitor (CGM) for people with type 1 diabetes.
“GlucoTrack’s approach to advancing solutions for the management of diabetes and prediabetes is both unique and innovative,” said Tapsak. “I consider myself fortunate to be able to join this exceptional team in developing technology that has the potential to help so many.”
Tapsak brings a wealth of experience
Rutherford, New Jersey-based GlucoTrack said in a news release that Tapsak joins the company from Diabetic Health. His previous company developed coatings utilized in CGM sensors and insulin infusion sets. Tapsak served as president at Diabetic Health.
His track record includes several diabetes management companies, according to GlucoTrack. Tapsak served as senior scientist at Dexcom and senior chemist at Medtronic. His name features as an inventor on 68 patents, with more than 50 of those assigned to Dexcom.
“Mark and I worked together in the early days of development at DexCom, and I am thrilled to be working with him again”, said Paul Goode, CEO and president of GlucoTrack. “By bringing together a veteran team with proficiency in the implantable device and glucose sensing space, we are looking to bring life-changing products to market that are designed to prioritize both health and comfort, enabling freedom from the pain and inconvenience currently plaguing patients with diabetes.”
